Veterinary Pharmacology Study Guide: Key Concepts for Clinical Practice

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Pharmacokinetic parameters (bioavailability, volume of distribution, clearance, half-life) are fundamental to rational veterinary drug dosing, with significant species-specific variations in absorption, metabolism, and excretion necessitating consultation of resources like the MSD Veterinary Manual.
• Pharmacodynamic principles, including receptor binding, potency (EC50), and efficacy (Emax), dictate drug response, with concepts like receptor reserve and desensitization explaining tolerance and withdrawal phenomena, particularly relevant for drugs like opioids and corticosteroids.
• Regulatory frameworks, such as FDA approval and extralabel use guidelines, alongside antimicrobial stewardship principles emphasizing judicious use and narrow-spectrum agents, are critical for legal and effective prescribing, especially in food animal practice where withdrawal periods are paramount.
• Species differences in drug metabolism (e.g., feline glucuronidation deficiency) and receptor distribution necessitate careful dose extrapolation, with network pharmacology offering hypothesis generation for nutraceuticals but not replacing species-specific clinical data.
• A structured approach to drug therapy planning involves confirming diagnosis, defining therapeutic objectives, selecting drug classes based on mechanism and patient factors (renal/hepatic function, pregnancy), choosing specific agents and regimens considering pharmacokinetic fit, and establishing clear monitoring parameters with action thresholds.
• Adverse drug reactions and drug interactions, particularly in polypharmacy scenarios, require vigilant monitoring for early detection through targeted laboratory tests (e.g., ALT/ALP for hepatotoxicity) and clinical assessment, with mandatory reporting to regulatory bodies like the FDA CVM.

This study guide condenses the pharmacological principles that underpin rational drug selection, dosing, and monitoring in veterinary practice. It is written for practicing veterinarians preparing for board examinations or seeking a structured refresher. The focus is on conceptual frameworks, mechanisms of action, and clinical decision logic, not on exhaustive drug lists. Species differences, regulatory constraints, and stewardship obligations are addressed where they alter clinical reasoning.

The guide answers three questions. First, how do drug disposition and receptor interactions determine therapeutic outcomes across species? Second, which pharmacokinetic and pharmacodynamic principles should drive dosing interval decisions and therapeutic drug monitoring? Third, how do regulatory frameworks and antimicrobial stewardship commitments shape prescribing behavior in production animal and companion animal practice? Later parts of this series apply these concepts to specific drug classes, adverse drug reaction management, and polypharmacy risk assessment.

At a Glance

Pharmacokinetic Principles That Drive Dosing Decisions

Pharmacokinetics describes what the body does to a drug. Four parameters govern most clinical decisions: bioavailability, volume of distribution, clearance, and half-life. Bioavailability after oral administration varies substantially between species due to differences in gastrointestinal pH, transit time, first-pass metabolism, and gut flora composition. Ruminants, for example, may degrade certain drugs in the rumen before absorption, while carnivores with shorter gastrointestinal tracts may absorb some compounds more rapidly. The MSD Veterinary Manual provides species-specific bioavailability data that should be consulted before extrapolating doses between species.

Volume of distribution (Vd) relates the amount of drug in the body to the plasma concentration. Drugs that are lipophilic or highly tissue-bound have large Vd values and require larger loading doses to achieve therapeutic plasma concentrations. Drugs confined to the vascular space, such as some large molecular weight antimicrobials, have small Vd values. Clearance, expressed as volume of plasma cleared per unit time, is the sum of hepatic metabolism and renal excretion. Clearance determines the maintenance dose rate, while half-life, which is derived from Vd and clearance, determines the dosing interval. In patients with renal or hepatic disease, clearance of specific drugs may be reduced, and dosing adjustments should be based on the organ responsible for elimination of the particular drug.

Pharmacodynamics and Receptor Theory

Pharmacodynamics describes what the drug does to the body. Most veterinary drugs produce effects through reversible binding to receptors, enzymes, ion channels, or transporters. The relationship between drug concentration at the effect site and the magnitude of response is typically described by the Hill equation, which defines potency (EC50) and efficacy (Emax). Potency matters for dosing but efficacy matters for therapeutic outcome. A drug can be potent yet have low maximal efficacy, and clinical drug selection should prioritize efficacy for the target condition.

Receptor reserve, spare receptors, and desensitization are concepts that explain why some drugs maintain effect at low receptor occupancy while others require near-complete occupancy. Chronic exposure to agonists can cause receptor downregulation, leading to tolerance. This is clinically relevant for drugs such as opioids, benzodiazepines, and corticosteroids. Conversely, chronic receptor blockade can cause upregulation, which contributes to withdrawal phenomena when the antagonist is discontinued abruptly.

Species Differences in Drug Response

Species variation in drug response arises from differences in metabolism, receptor distribution, protein binding, and excretion pathways. Cats are deficient in glucuronosyltransferase activity, which slows elimination of drugs such as acetaminophen and some NSAIDs. Dogs have higher renal clearance of some basic drugs than humans. Horses have a large cecum where microbial metabolism can alter drug disposition, and they are particularly sensitive to drugs that affect the gastrointestinal flora. Ruminants require consideration of ruminal drug degradation and the potential for antimicrobial residues to disrupt rumen fermentation.

These differences mean that allometric scaling from one species to another is unreliable for many drugs. The MSD Veterinary Manual publishes species-specific pharmacokinetic data and dosing recommendations that reflect measured differences instead of extrapolation. When published data are absent for a species, clinicians should acknowledge the uncertainty and monitor therapeutic response and adverse effects closely.

Regulatory Frameworks Governing Drug Use

Drug approval and use are governed by regulatory bodies that vary by jurisdiction. In the United States, the Food and Drug Administration Center for Veterinary Medicine approves animal drugs for specific species and indications, establishes labeling requirements, and regulates extralabel use under the Animal Medicinal Drug Use Clarification Act. The FDA animal drug information portal provides access to approved labels, withdrawal information, and adverse event reporting systems. Extralabel use is permitted only under specific conditions, including the existence of a valid veterinarian-client-patient relationship and the absence of an approved drug that meets the clinical need.

Internationally, the World Organization for Animal Health publishes standards that influence drug residue monitoring and trade-related requirements. The WOAH terrestrial animal health code addresses veterinary drug residues in the context of international trade and food safety. Veterinarians working with production animals must be aware of the withdrawal periods established by their national regulatory authority and must document extralabel use decisions. Withdrawal periods are jurisdiction-specific and should be verified against current regulatory sources before dispensing.

Antimicrobial Stewardship as a Pharmacological Obligation

Antimicrobial stewardship is not an administrative afterthought, it is a pharmacological discipline that preserves drug efficacy. The AVMA antimicrobial stewardship resources outline principles of judicious use, including selecting the narrowest effective agent, using the correct dose and duration, and avoiding antimicrobials that are critically important to human medicine when alternatives exist. Stewardship also requires culture and susceptibility testing when infection is severe or treatment has failed, and it requires re-evaluation of therapy once culture results are available.

From a pharmacological perspective, stewardship means understanding the relationship between drug exposure and resistance selection. Subtherapeutic concentrations can select for resistant subpopulations, while unnecessarily prolonged therapy increases selective pressure without additional clinical benefit. The duration of therapy should be based on clinical resolution criteria instead of fixed calendar days where evidence supports this approach. In production animal practice, stewardship also includes consideration of metaphylaxis and group treatment protocols, which should be justified by disease prevalence and susceptibility data instead of convenience.

Nutraceuticals and Network Pharmacology in Veterinary Contexts

Veterinarians increasingly encounter nutraceuticals and dietary supplements in clinical practice, often with limited pharmacokinetic data. Network pharmacology approaches have been applied to predict the molecular targets of compounds such as naringenin, a citrus flavonoid with anti-inflammatory properties. A network pharmacology review of naringenin identified core target genes including PTGS2, ESR1, CAT, CASP3, MAPK1, and AKT1, and implicated HIF-1, estrogen, TNF, and NF-κB signaling pathways in its immunomodulatory effects. Similar approaches have been used to investigate coenzyme Q10 for oocyte aging, identifying antioxidant and mitochondrial function pathways as putative mechanisms. These analyzes generate hypotheses, but they do not substitute for species-specific clinical efficacy data. Practitioners should evaluate nutraceuticals with the same skepticism applied to any drug with limited evidence, and they should discuss the uncertainty with clients.

Building a Practical Drug Therapy Plan

The transition from pharmacology theory to a prescribing decision requires a structured approach. A useful framework moves through five steps: confirm the diagnosis, define the therapeutic objective, select the drug class, choose the specific agent and regimen, and establish monitoring criteria. Each step has explicit decision points where patient status, species, or production system changes the correct answer.

Step 1: Confirm the Diagnosis and Define the Therapeutic Objective

Prescribing begins with a diagnosis, not a drug. The therapeutic objective must be stated in measurable terms. For an infection, the objective is bacterial eradication or clinical cure. For pain, it is a defined reduction in a pain score or return to weight-bearing. For heart failure, it is resolution of pulmonary edema signs with stable renal function.

The objective determines the endpoint of therapy and the monitoring schedule. A static objective, such as "give antibiotics for 10 days," invites premature discontinuation or unnecessary prolongation. A dynamic objective, such as "resolution of fever and leukocytosis with return to normal appetite," allows therapy to be tailored to response.

Step 2: Select the Drug Class Based on Mechanism and Patient Factors

Drug class selection follows from the pathophysiology and the drug's pharmacodynamic profile. For bacterial infections, class selection depends on the suspected organizm, tissue penetration, and the infection site. For example, a gram-negative urinary tract infection may respond to a beta-lactam, but a fluoroquinolone may be preferred when intracellular organizms or biofilm-associated infections are suspected.

Patient factors that change class selection include:

• Renal or hepatic function, which alters clearance of drugs such as aminoglycosides, macrolides, and NSAIDs
• Pregnancy or lactation status, which restricts options such as tetracyclines and fluoroquinolones
• Age, with neonatal patients having reduced hepatic enzyme activity and immature renal clearance
• Concurrent disease, such as epilepsy, which precludes drugs that lower the seizure threshold
• Production status, where milk or meat withdrawal periods constrain the choice of agent

Step 3: Choose the Specific Agent and Regimen

Within a class, the specific agent is chosen based on pharmacokinetic fit, formulation, cost, and regulatory approval. The regimen, including dose, interval, and route, is derived from the drug's half-life, the site of infection, and the patient's metabolic capacity.

The dose interval should be based on the relationship between the drug's half-life and the time above the minimum inhibitory concentration (MIC) for time-dependent drugs, or the peak concentration to MIC ratio for concentration-dependent drugs. A drug with a short half-life given once daily may be subtherapeutic for a time-dependent agent. Conversely, a concentration-dependent drug with a long half-life may accumulate if dosed too frequently.

Current formulary and label references must be consulted for specific doses. The FDA Center for Veterinary Medicine provides approved labeling and regulatory information for animal drugs, and the MSD Veterinary Manual offers species-specific clinical pharmacology guidance. Doses are not interchangeable across species without pharmacokinetic justification.

Step 4: Establish Monitoring Parameters

Monitoring serves two purposes: confirming efficacy and detecting toxicity. The monitoring plan should specify the parameter, the timing, and the action threshold.

The monitoring plan must be documented in the medical record, including the baseline values, the scheduled rechecks, and the criteria for dose adjustment or discontinuation.

Drug Interactions and Polypharmacy

Polypharmacy is common in veterinary patients, particularly in geriatric, oncologic, and critically ill populations. The risk of an adverse drug interaction increases with the number of concurrent medications. A structured review of the complete medication list, including supplements and topical products, is required before adding any new drug.

Major interaction mechanisms include:

• Cytochrome P450 enzyme induction or inhibition, which alters the metabolism of co-administered drugs
• Protein binding displacement, which transiently increases the free fraction of a highly bound drug
• Additive pharmacodynamic effects, such as concurrent use of two NSAIDs or two serotonergic drugs
• Altered renal excretion, where one drug reduces the clearance of another

The clinical consequence of an interaction depends on the therapeutic index of the affected drug. A narrow-therapeutic-index drug, such as digoxin or phenobarbital, requires closer monitoring when an interacting drug is added or withdrawn. The AVMA practice resources provide professional guidance on medication safety and adverse event reporting.

Adverse Drug Reactions and Reporting

Adverse drug reactions are distinct from therapeutic failure. An adverse reaction is a harmful or unintended response to a drug administered at a normal dose. Reactions may be dose-dependent, such as aminoglycoside nephrotoxicity, or idiosyncratic, such as a hypersensitivity reaction to a sulfonamide.

The diagnostic approach to a suspected adverse reaction includes:

• Temporal association between drug administration and the onset of signs
• Exclusion of the underlying disease as the cause of the signs
• Dechallenge, where withdrawal of the drug leads to resolution
• Rechallenge, where re-administration reproduces the signs, only when clinically safe

Reporting suspected adverse reactions to the appropriate regulatory body is a professional obligation. The FDA Center for Veterinary Medicine accepts adverse event reports for approved animal drugs and provides guidance on reporting procedures. Reports contribute to the detection of rare or delayed reactions that are not identified in pre-approval studies.

Antimicrobial Stewardship in Prescribing Decisions

Antimicrobial stewardship is an integral part of the prescribing decision, not an administrative afterthought. The AVMA antimicrobial use and stewardship guidance outlines principles for judicious use, including using the narrowest spectrum agent that is likely to be effective, using the shortest duration consistent with clinical cure, and avoiding antimicrobials for viral infections or as growth promoters.

The decision to use a critically important antimicrobial, such as a fluoroquinolone or a third-generation cephalosporin, requires documented justification. The justification should include culture and susceptibility results when available, the failure of a narrower-spectrum agent, or a clinical condition where a narrow-spectrum agent is unlikely to be effective.

In production animal practice, the choice of antimicrobial also affects food safety and trade. The WOAH terrestrial animal health standards address the responsible use of antimicrobials in animals and the harmonization of residue monitoring. Withdrawal periods must be verified against the label and, for extralabel use, against the regulatory framework of the jurisdiction.

Self-Assessment Questions

1. A 7-year-old dog with chronic kidney disease (IRIS stage 2) requires an NSAID for osteoarthritis. Which monitoring parameters would you establish before and during therapy, and what action threshold would trigger discontinuation?

1. A horse with a suspected bacterial pneumonia has been treated with a time-dependent antimicrobial administered once daily. The half-life of the drug is 4 hours. What pharmacodynamic principle does this regimen violate, and what alternative dosing strategy would you consider?

1. A cat on phenobarbital for epilepsy develops a new infection requiring a macrolide antibiotic. What drug interaction mechanism should you consider, and how would you adjust the monitoring plan?

1. A dairy cow requires treatment for mastitis with an extralabel drug. What regulatory and food safety considerations must be addressed before prescribing, and where would you find the relevant standards?

1. A dog on chronic prednisolone therapy develops gastrointestinal ulceration. The owner reports that the dog also receives a daily aspirin. What pharmacodynamic interaction is present, and how does this change the therapeutic plan?

Recognized Complications and Early Detection

Therapeutic failure in veterinary pharmacology usually follows a recognizable pattern. The most common complications are adverse drug reactions, drug interactions, and loss of effect through resistance or tolerance. Each has identifiable early markers.

Adverse drug reactions may present as predictable dose-dependent toxicity or as idiosyncratic responses. Early detection depends on knowing the target organ profile of each drug class. Hepatotoxic drugs warrant serial liver enzyme measurement before clinical signs appear. Nephrotoxic agents require urine specific gravity, proteinuria assessment, and creatinine monitoring. Myelosuppressive drugs demand complete blood count at the nadir expected for that agent. The FDA Center for Veterinary Medicine animal drug information provides label-based toxicity data that supports scheduling these checks.

Drug interactions are frequently missed because the clinician does not maintain a complete medication list. Polypharmacy in geriatric patients, particularly those on chronic nonsteroidal anti-inflammatory drugs, glucocorticoids, and angiotensin-converting enzyme inhibitors, creates predictable risk. Early detection requires a structured medication reconciliation at every visit, including owner-administered supplements and topical products.

Loss of effect presents as declining clinical response at a previously effective dose. For antimicrobials, this raises the possibility of resistance and warrants culture and susceptibility testing instead of empirical dose escalation. For analgesic or anticonvulsant therapy, tolerance or disease progression must be distinguished. The AVMA antimicrobial stewardship resources emphasize that repeated empirical escalation without diagnostic confirmation is a stewardship failure.

Common Errors and Corrective Action

Less experienced clinicians often confuse drug concentration with drug effect. A patient that appears unresponsive to a drug may have poor bioavailability, rapid clearance, or an incorrect diagnosis instead of an inadequate dose. The corrective action is to verify the diagnosis, confirm owner compliance, and consider therapeutic drug monitoring where assays exist.

Dosing by body weight alone ignores metabolic differences. Obese patients have altered volume of distribution for lipophilic drugs, and lean body mass is a better scaling basis for many agents. Neonates and geriatric patients have reduced renal and hepatic clearance. The MSD Veterinary Manual professional edition provides species-specific dosing guidance that accounts for these physiological variables.

A second common error is extrapolating doses across species without adjustment. Cats are deficient in glucuronidation pathways, making them susceptible to drugs that are safe in dogs. Horses have a large volume of distribution for many agents and unique gastrointestinal sensitivity to oral antimicrobials. Cross-species extrapolation should be limited to drug classes with wide therapeutic indices and should always be checked against a current formulary.

A third error is stopping antimicrobial therapy at the first sign of clinical improvement. This selects for resistant subpopulations and increases the risk of relapse. The corrective action is to define the treatment duration at the time of prescribing, based on the known natural history of the condition, and to communicate that endpoint clearly to the owner.

Limitations of Current Evidence

The evidence base in veterinary pharmacology has substantial gaps. Many drug labels reflect studies in young, healthy animals, not the aged or comorbid patients seen in practice. Extrapolation from human pharmacology is common but imperfect, particularly for drugs with species-specific metabolism.

Network pharmacology studies, such as those examining naringenin as a natural immunomodulator in T cell-mediated autoimmune disease and coenzyme Q10 effects on oocyte aging, illustrate both the promise and the limits of computational approaches. These studies identify candidate targets and pathways but do not establish clinical efficacy or safety in veterinary patients. They generate hypotheses that require prospective clinical validation.

Expert opinion still differs on several practical questions. The role of adjunctive immunomodulatory therapy in autoimmune disease, the optimal duration of antimicrobial therapy for deep infections, and the value of routine therapeutic drug monitoring for anticonvulsants are all areas where published evidence is insufficient to mandate a single approach. Clinicians should acknowledge this uncertainty and document their reasoning.

Referral, Consultation, and Reporting

Referral is warranted when the therapeutic index is narrow, the condition is refractory to first-line therapy, or the patient has significant comorbidity that complicates drug selection. Specialist consultation in clinical pharmacology or the relevant organ system is appropriate before using drugs with limited veterinary safety data.

Laboratory involvement is indicated for therapeutic drug monitoring of drugs with established assays, for pharmacogenetic testing where relevant, and for confirmation of suspected adverse drug reactions. Clinical pathologists can also assist in distinguishing drug-induced disease from progression of the underlying condition.

Regulatory reporting is required for adverse drug events involving approved veterinary products. The FDA Center for Veterinary Medicine maintains the adverse event reporting system, and practitioners should report both expected and unexpected reactions. Suspected lack of efficacy for antimicrobials may also warrant reporting, particularly for drugs used in food animals where WOAH terrestrial animal health standards address resistance surveillance and trade implications.

Troubleshooting Table

Frequently Asked Questions

How Do I Choose Between Cost and Efficacy When Selecting a Drug for a Client with Limited Resources?

Start by defining the non-negotiable therapeutic objective, then rank available options by mechanism, safety margin, and monitoring feasibility. A cheaper drug that requires intensive monitoring or has a narrow safety index may cost more overall when complications arise. Consider whether a longer course of a less expensive agent achieves the same endpoint with acceptable resistance risk. For production animals, factor in withdrawal periods and their economic impact on the operation. Consult the FDA Center for Veterinary Medicine animal drug information for approved indications and labeling that may inform cost-effective choices. When the ideal agent is unaffordable, document the financial constraint in the record and select the best alternative that still meets the therapeutic goal.

What Adjustments Should I Make When the Recommended Monitoring Equipment Is Not Available?

Use clinical endpoints that do not require specialized equipment. Serial body weight, mucous membrane color, capillary refill time, urine output, and appetite are reliable proxies for many drug effects. For drugs where therapeutic drug monitoring is standard but unavailable, extend observation intervals and rely on dose-dependent adverse effect surveillance. If you cannot measure a parameter that is critical for safety, choose a drug with a wider therapeutic index or a different elimination pathway. The MSD Veterinary Manual professional edition provides species-specific guidance on clinical assessment that substitutes for laboratory monitoring. Record explicitly in the medical record which parameters were assessed and which were not, and state the rationale for proceeding without them.

How Does My Approach to Dosing Change When Treating a Species for Which the Drug Is Not Labeled?

Extrapolate from the closest related species using allometric scaling, then adjust for known species differences in metabolism, protein binding, and elimination. Recognize that extrapolation error increases with phylogenetic distance. Verify whether the drug is prohibited or restricted in the target species under your jurisdiction. For food animals, extralabel use carries specific residue avoidance obligations that differ by region, consult the WOAH terrestrial animal health standards for international trade considerations. Document the basis for your dose selection, including the source species, scaling method, and any published safety data. If no safety data exist for the target species, inform the owner of the uncertainty and obtain consent before proceeding.

What Records Must I Keep for Controlled Substances and Antimicrobials, and How Long Should I Retain Them?

Maintain a complete drug log that includes drug name, concentration, amount dispensed or administered, patient identification, date, and prescribing veterinarian. For controlled substances, reconcile inventory at intervals defined by your jurisdiction and keep records separate from the general medical record. For antimicrobials, record the indication, drug, dose, duration, and culture or susceptibility results when available. This documentation supports stewardship review and defends clinical decisions if questioned. The AVMA antimicrobial use and stewardship resources outline professional expectations for judicious use documentation. Retention periods vary by jurisdiction and practice type, when in doubt, retain records for at least the minimum period required for controlled substances in your region, which is typically longer than for general medical records.

How Should I Explain a Drug Withdrawal Period or a Potential Adverse Effect to a Client Who Wants to Proceed Anyway?

State the risk in concrete terms tied to the client's own situation, such as the specific consequence for a child, another pet, or a food product. Explain that the withdrawal period exists because drug residues cannot be reliably removed by cooking or freezing. If the client insists on proceeding against your recommendation, document the discussion, the client's decision, and the specific warnings you provided. For food animals, make clear that marketing animals before the withdrawal period ends may violate residue regulations and could have legal consequences. The FDA Center for Veterinary Medicine provides residue information that supports these conversations. You are not obligated to comply with a request that places public health at risk, and you may decline to dispense the drug.

How Do I Manage a Suspected Adverse Drug Reaction When the Clinical Signs Are Nonspecific?

Stop the suspected drug if the reaction is severe or progressing, and provide supportive care directed at the presenting signs. Collect a thorough timeline linking drug administration to sign onset, and note any concurrent medications that could confound the association. If the reaction is mild and the drug is essential, consider dose reduction or temporary discontinuation with rechallenge under close observation. Report the reaction through your national pharmacovigilance system, as individual reports contribute to signal detection across the profession. The FDA Center for Veterinary Medicine adverse event reporting pathway is one example of such a system. Document your differential diagnoses, the evidence for drug attribution, and the outcome in the medical record.

Related Clinical & Scientific Guides

• Veterinary Formulary Essentials: Navigating Drug References
• Drug Interactions with Antiepileptic Drugs in Veterinary Patients: Managing Polypharmacy
• Drug Interactions with Corticosteroids in Veterinary Patients: A Comprehensive Review

References and Further Reading

• Naringenin as a natural immunomodulator against T cell-mediated autoimmune diseases: literature review and network-based pharmacology study.. 2023.
• The Therapeutic Targets of Fingolimod (FTY720) Are Involved in Pathological Processes in the Frontal Cortex of Alzheimer's Disease Patients: A Network Pharmacology Study.. 2021.
• Systematic Understanding of Anti-Aging Effect of Coenzyme Q10 on Oocyte Through a Network Pharmacology Approach.. 2022.
• FDA Center for Veterinary Medicine: Animal Drug Information. FDA CVM.
• AVMA Antimicrobial Use and Stewardship. American Veterinary Medical Association.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.
• American Veterinary Medical Association Practice Resources. American Veterinary Medical Association.
• WOAH Terrestrial Animal Health Code. WOAH.

Related Articles

• Veterinary Pharmacology and Therapeutics: Core Concepts for Clinicians
• Drug Interactions in Polypharmacy: A Clinical Decision Framework
• Pharmacokinetics in Veterinary Patients: Clinical Application of Drug Disposition
• Antimicrobial Stewardship in Equine Practice: Challenges and Solutions
• Antimicrobial Stewardship in Small Animal Practice: Implementing a Program

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.